Pacer Advisors Inc. Sells 880,384 Shares of Cencora, Inc. $COR

Pacer Advisors Inc. decreased its stake in shares of Cencora, Inc. (NYSE:COR) by 97.8% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 20,187 shares of the company’s stock after selling 880,384 shares during the period. Pacer Advisors Inc.’s holdings in Cencora were worth $6,309,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares in the last quarter. Vermillion & White Wealth Management Group LLC increased its holdings in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after acquiring an additional 43 shares during the period. Caldwell Trust Co purchased a new stake in Cencora in the 2nd quarter worth approximately $46,000. Capital A Wealth Management LLC lifted its stake in Cencora by 3,975.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock worth $49,000 after purchasing an additional 159 shares in the last quarter. Finally, Twin Peaks Wealth Advisors LLC bought a new position in Cencora in the 2nd quarter valued at $52,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on COR. Mizuho upped their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. TD Cowen upped their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Robert W. Baird set a $392.00 price objective on Cencora in a report on Tuesday, December 16th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $373.25.

Insiders Place Their Bets

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $343.45, for a total value of $1,750,221.20. Following the transaction, the chief executive officer directly owned 68,059 shares in the company, valued at $23,374,863.55. This trade represents a 6.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 20,317 shares of company stock valued at $7,009,260 over the last three months. Insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of Cencora stock opened at $340.08 on Tuesday. The firm has a market capitalization of $65.97 billion, a PE ratio of 42.78, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $377.54. The business’s 50-day moving average price is $348.91 and its 200-day moving average price is $315.59.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same quarter in the prior year, the firm earned $3.34 earnings per share. Cencora’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is 30.19%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.